Indication
Severe recalcitrant psoriasis
Severe recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin. Read more about Severe recalcitrant psoriasis
96 drugs 68 manufacturers
Drugs that treat it
Common Severe recalcitrant psoriasis therapies.
METHOTREXATE (methotrexate sodium)
METHOTREXATE (methotrexate sodium)
METHOTREXATE (methotrexate sodium)
METHOTREXATE (methotrexate sodium)
ACITRETIN
METHOTREXATE (methotrexate sodium)
METHOTREXATE (methotrexate sodium)
ACITRETIN
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSevere recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin.
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies.
Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability.
- nih.gov
Severe recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability
- fda.gov
Severe recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin
- psoriasiscouncil.org
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies
- webmd.com
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies
- dermsquared.com
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, er...
- nih.gov
Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability
- nih.gov
Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability
Personalize your experience
Follow Severe recalcitrant psoriasis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.